Trial NCT05546411

View at ClinicalTrials.gov 
Org. Study IDs: 22-314

Last trial update was posted on 2023-11-01

MeSH Interventions

Camptothecin Fluorouracil Irinotecan Leucovorin Levoleucovorin Oxaliplatin

MeSH Conditions

Adenocarcinoma Pancreatic Neoplasms

Other Conditions

Borderline Resectable Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma Pancreatic Cancer Resectable Pancreatic Cancer

Stopping Reasons

Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are stopping all clinical development of NIS793 in pancreatic cancer, effective immediately.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID